Fresenius Kabi Highlights Commitment to Combating Antimicrobial Resistance During AMR Awareness Week

Fresenius Kabi Highlights Commitment to Combating Antimicrobial Resistance During AMR Awareness Week

(IN BRIEF) Fresenius Kabi is addressing the global threat of antimicrobial resistance (AMR), which causes millions of deaths annually, through sustainable manufacturing, improved antibiotic access, and promoting responsible use. During AMR Awareness Week, the company highlighted its commitment to reducing resistance by providing 57 antibiotic treatments, adhering to strict ecological standards in production, and advocating for correct antibiotic usage by healthcare professionals and patients. With collaboration across healthcare and global organizations, Fresenius Kabi aims to improve outcomes, curb resistant bacteria, and preserve the effectiveness of antibiotics for future generations.

(PRESS RELEASE) BAD HOMBURG, 20-Nov-2024 — /EuropaWire/ — Antimicrobial resistance (AMR) poses a growing global threat, causing millions of deaths each year as bacteria evolve to resist antibiotics. Fresenius Kabi, a leading manufacturer of intravenously administered generic medicines, is taking action to address this urgent issue through sustainable production, increased access, and responsible use of antibiotics.

During Antimicrobial Resistance Awareness Week, a global initiative led by the World Health Organization, Fresenius Kabi is urging healthcare professionals, policymakers, and the public to act against the growing danger of AMR. The company emphasizes the critical role of access to antibiotics, responsible manufacturing, and appropriate usage in mitigating the spread of resistant bacteria.

“Antibiotics are lifesaving treatments, but their effectiveness is threatened by misuse and overuse,” said Minodora Westphal, Senior Manager Innovation Strategy at Fresenius Kabi. “By ensuring responsible production and advocating for proper use, we aim to improve patient outcomes and reduce the risk of resistance.”

The Growing Toll of AMR

In 2021, over 1.14 million deaths were directly attributed to AMR, with an additional 4.71 million deaths linked to the issue as a contributing factor. Projections indicate that from 2025 to 2050, infections caused by AMR could result in over 39 million deaths, surpassing cancer as a leading cause of mortality.

Access to Antibiotics

Fresenius Kabi provides 57 antibiotic treatments, ensuring accessibility through sustainable manufacturing and active collaboration with healthcare professionals and global organizations. By improving access and promoting proper use, the company seeks to limit the development of resistant bacteria.

Sustainable Manufacturing Practices

Adhering to the Antibiotic Manufacturing Standard, Fresenius Kabi minimizes ecological risks associated with antibiotic production. The company implements stringent wastewater management measures to prevent the release of resistant bacteria into the environment, reinforcing its commitment to environmental responsibility.

Promoting Responsible Use

Fresenius Kabi advocates for behavioral changes among healthcare professionals and encourages patients to follow medical guidance, optimizing antibiotic treatments and reducing the spread of resistance. The company also emphasizes preventive measures, including good hygiene and appropriate vaccinations, to curb infections and preserve the effectiveness of existing antibiotics.

“As a generics manufacturer, we are committed to balancing greater access to antibiotics with the responsibility of ensuring their correct use,” said David Jauch, Vice President Government Affairs and Policy at Fresenius Kabi. “Treating patients with the right antibiotic for their specific infection is crucial to preventing further resistance.”

Through collaborative efforts, sustainable practices, and public advocacy, Fresenius Kabi continues to address the escalating challenge of AMR, contributing to a safer and healthier future for all.

Media Contact:

Tel: +49 6172 686 0
email: communication@fresenius-kabi.com

SOURCE: Fresenius AG